• For a Sustainable Pharma Supply Chain: Schreiner MediPharm is a Founding Member of the “Alliance to Zero”

    Enhancing sustainability along the pharmaceutical supply chain: As founders of the “Alliance to Zero,” eight renowned players have been jointly pursuing this aim since June 2021. The purpose of the non-profit partnership is to support pharmaceutical and biotech companies in their transition to net-zero emissions in line with the Paris Climate Agreement. Schreiner MediPharm, as an expert in pharmaceutical specialty labels, is one of the founding members.

  • GUALAPACK ACCELERATES SUSTAINABLE PACKAGING IN BRAZIL

     Gualapack Spa is announcing its plans for expansion in Brazil, as part of the Group’s continued efforts for a sustainable, global growth through vertical integration. 

    Gualapack strongly pursues international development to support its positioning on the global market as the world leader in pre-made spouted pouches and a global player in the flexible packaging industry. Brazil has been a strategic area for the company's growth since 2015, when the Group opened the dedicated subsidiary Gualapack Brasil in Iperó / São Paulo by merging with pouch producer Tradbor.

  • Marchesini Group attends CPhI Worldwide with a Print&Check solution to meet Track&Trace needs

    Milan (Italy) – From 9 to 11 November, one of the most eagerly awaited events in the pharmaceutical sector will be held again at the Milan trade fair: CPhI Worldwide, which, after almost two years, will allow pharmaceutical companies to meet again and directly discuss the challenges they face in the coming years.

  • LES EAUX DE CHANEL – Elegance and simplicity with a sustainable SULAPAC cap on top

    CHANEL has just announced new LES EAUX DE CHANEL fragrance bottle caps made with biobased Sulapac® material.

    Sustainable innovation approach

    It all began with a desire. In 2018, LES EAUX DE CHANEL introduced a new olfactory world to the fragrances of the House: a singular collection, inspired by Mademoiselle Coco Chanel’s favorite places, fueled by the imaginary and composed around freshness.

  • At INTERPHEX NYC, MG America to Premier Precision Wraparound Labeler for Vials, and Robust 10-Lane Capsule Checkweigher

    WL-1-RT Wraparound Vial Labeling Machine ideal for high-speed vaccine production; Anritsu 10-lane 100% Capsule Checkweigher features novel handling mechanism for reliable feed and reject functions.

  • Owen Mumford launches new Aidaptus auto-injector

    News: 

    Aidaptus is a two-step, spring-powered, single use auto-injector with a design that accommodates both 1mL and 2.25 mL prefilled glass syringes in the same base device. It also features stopper sensing technology with a self-adjusting plunger that automatically adapts to the individual stopper positions and different fill volumes in each syringe, with no change parts required. The auto-injector is available with two different spring strengths to accommodate a variety of drug viscosities.

    Aidaptus has a patient-centric design with automatic needle insertion that provides a simple and consistent user experience. The stopper sensing technology, coupled with the independent, two-phase needle insertion and drug delivery, reduces any impact forces on the syringe, mitigating the risk of syringe breakages during use. With a needle that is shielded before, during and after use, Aidaptus provides reassurance to users who are new to auto-injectors as well as those who experience needle phobia. It can also give users confidence that the injection has been successfully completed with an audible notification at the start and end of the procedure. In addition, a bright yellow plunger rod is visible though a large window in the device confirming the end of injection.

    Aidaptus is available in two base platform options: a clear outer body with colour overwrap permitting rapid selection of window size or traditional opaque housing, offering versatility for both branding and customisation as well as options for market segmentation and life cycle management. Its highly compact nature reflects the excellence in sustainable design and human factors engineering used throughout its development; coupled with consideration for ease of final assembly through application of design for manufacture (DfM) principles.

    Michael Earl, director, Owen Mumford Pharmaceutical Services, said: “Our Aidaptus auto-injector platform has been designed to facilitate the growing market for subcutaneous injections used to treat a variety of chronic diseases like rheumatoid arthritis, Crohns’ disease and multiple sclerosis. With the increasing move towards treatment outside of the acute care setting, Aidaptus will help patients to self-administer their individual therapies using a simple and easy to use device. At the same time, this auto-injector can help to reduce complexity and risk in supply chain and final assembly for pharmaceutical and biotechnology companies’ combination products thanks to its ability to adapt to different syringe sizes and fill volumes. It is often the case that during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now the device does not have to be changed as well.”

    Aidaptus has been designed to meet the challenges of changes to drug formulation or injected volume and can therefore help reduce risk during drug development and lifecycle management.

  • At INTERPHEX NYC, TurboFil to Showcase Module for Simplified, Automated Syringe Filling & Assembly

    Equipment specialist also will exhibit new benchtop syringe filler

    ideal for compounding pharmacies

  • RFID inlay Tracks single-dose drugs to patients’ bedside

    News: 

    The new product, known as the GB32U9, is SML's smallest inlay to date, according to the report in RFID Journal and is engineered to transmit data effectively when applied to vials filled with liquid and made from plastic or glass packaging. 

    The Group is currently in the process of delivering the new inlays to at least one pharmaceutical company, but the RFID technology provider is also in discussions with other US-based businesses. The company began building RFID tag products for the pharmaceutical industry three years ago, according toDean Frew, SML Group's chief technology officer and senior VP of RFID solutions. However, he adds, widespread interest in the technology's use for drugs and other controlled substances at hospitals didn't see dramatic growth until 2019 and 2020.

    "Just like with every other vertical," states Frew, "companies [in the pharmaceutical industry] are seeing what can be done with item-level RFID, and that leads to growing demand," both for the tags and for solutions that utilize the tag-read data to improve operations.Another accelerator to that growth is the advent of a new standard for pharmaceutical RFID tags, created by the DoseID consortium(newsletter 14/10/2020.) The GB32U9is among the first inlays to gain Spec S certification from the program.

    The GB32U9, inlay isspecifically designed for unit-of-use medications in pharmaceutical applications, leverages  NXP's latest chip, the UCODE 9. According to Frew, the inlay provides high quality and rapid inventory countingin dense RFID tag populations.The challenge, he says, was to design a tag that would not detune when attached to a liquid-filled product. The company created an antenna that responds reliably in the presence of liquids, as well as a variety of other materials, including plastics or glass. The antenna must also work despite its very small size.The inlay's small design means it fits on a wide range of pharmaceutical products.

    The GB32U9 was designed with auto-adjust technology, unique brand identifiers and a pre-serialized 96-bit Electronic Product Code (EPC). Its antenna measures 20mm by 10mm with a wet paper face size of 26mm by 12mm.Typically, the tags will be applied at the fill line by a pharmaceutical company, after which they can be read throughout the supply chain. 

    The small size and material challenges mean the read range is shorter than standard UHF RFID tags, with a range of about 1m, but that varies depending on the environment and the type of reader being used. However for most drug products this is not a major issue, says Frew.The inlay is available now, following approximately 18 months of engineering and testing.

  • Interphex New York: Marchesini Group presents three machines for the pharmaceutical and nutraceutical market

    New York (USA) – Marchesini Group will participate at Interphex exhibition, a reference point for the pharmaceutical industries that will meet in New York from 19th  to 21st October to discuss new technologies and market trends.

  • Pages